Billings Clinic
Especially For:

Clinical Trials

Title   Brain (N0577): Anaplastic Glioma, First Line
Description   Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

IRB Number   NCCTG N0577
Category   Brain
Inclusion/Notes   Pt must sign a preconsent prior to enrolling, for tissue testing

Newly diagnosed and =3 months from surgical diagnosis.

Histological confirmation of anaplastic glioma (oligodendroglioma, mixed, or
astrocytoma [WHO grade III]), as determined by pre-registration central
pathology review, and tumor is also co-deleted for 1p and 19q. NOTE: Mixed
gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic
predominance, as long as the tumor is also co-deleted for 1p and 19q.
Status   Active
Start Date   06/10/2011
Principal Investigator (PI)   Venu Thirukonda, MD
Contact Name   Liane Bates, RN
Contact Email   lbates1@billingsclinic.org
Phone   (406) 435-7482
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.